Duane Schulthess is the Managing Director of Vital Transformation, a consultancy focused on quantifying and defining innovation and change in the healthcare sector. He regularly works with regulators, multi-national corporations, governments, and stakeholder groups, clarifying the impact of health policy changes and technological innovations.
He has been a speaker at many leading international conferences including BIO, the European Health Forum Gastein, DIA, and The Basel Biozentrum. Mr. Schulthess’ 2019 BMJ publication titled “Are CAR-T therapies living up to their hype?” is considered a ground-breaking analysis in the field of real-world evidence, and has been cited in presentations by the European Medicines Agency and EUnetHTA.
Previously, Duane was the EMEA Head of Corporate Development of The Wall Street Journal and was the Commercial Director of Science|Business. He has a BA Magna Cum Laude from the University of the Pacific where he was also nominated to the Phi Kappa Phi honor society, and an MBA with Distinction from KU Leuven’s Vlerick Management School. From 1988-91, he was a recipient of a Leverhulme Trust Fellowship at the Royal Academy of Music in London where he won several music performance prizes and competitions while also studying economics on an international exchange program at Regent’s College. He was recently appointed as a senior associate of the UK’s Royal Society of Medicine.